Dr. Phillip Frost is the chairman and CEO at OPKO Health, Inc., a biopharmaceutical and diagnostics company.
Dr. Frost was born in Philadelphia in 1936. He earned his undergraduate degree at the University of Pennsylvania, and his M.D. at the Albert Einstein College of Medicine.
Following university, he served as a lieutenant commander for the U.S. Public Health Service at the National Cancer Institute. He then worked as a dermatology professor at the University of Miami School of Medicine, and later served as chair of Mt. Sinai Medical Center’s dermatology department.
Frost joined Key Pharmaceuticals in 1972, where he reformulated its asthma drug and then sold the company for $836 million in 1986. He served as chair and CEO for generic drugmaker, Ivax, from 1987 to 2006, when it was acquired by Teva Pharmaceutical Industries. He sat on Teva’s board until 2015.
Presently, Dr. Frost serves as OPKO Health’s CEO, a role he has held since 2007. The company is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products.
Dr. Frost is also a director of Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases.
In September 2018, the SEC accused Dr. Frost of participating in a "pump-and-dump" scheme that generated over $27 million in unlawful stock sales. He settled in December 2018 without admitting or denying the allegations.
Dr. Frost sits on numerous boards and has a long history of philanthropy. His financial gifts include a $33 million donation to the University of Miami School of Music in 2003, then the largest gift to a university music school in the U.S. The school was subsequently renamed the Phillip and Patricia Frost School of Music. In 2011, he gave $35 million for the construction of a new building for the Miami Science Museum, to be named the Patricia & Phillip Frost Science Museum, and in 2015, he gave an additional $10 million toward the museum’s Frost Planetarium.
He is married to Patrica Orr, and they live on Star Island, Miami Beach.
What is Phillip Frost's net worth?
The estimated net worth of Phillip Frost is at least $327.31 million as of December 13th, 2024. Dr. Frost owns 212,536,477 shares of OPKO Health stock worth more than $327,306,175 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Frost may own. Additionally, Dr. Frost receives an annual salary of $1,450,000.00 as CEO at OPKO Health. Learn More about Phillip Frost's net worth.
How old is Phillip Frost?
What is Phillip Frost's salary?
How do I contact Phillip Frost?
Has Phillip Frost been buying or selling shares of OPKO Health?
During the last ninety days, Phillip Frost has bought $2,024,604.66 in OPKO Health stock. Most recently, on Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $198,750.00. Following the completion of the transaction, the chief executive officer now directly owns 212,536,477 shares of the company's stock, valued at $337,932,998.43. Learn More on Phillip Frost's trading history.
Who are OPKO Health's active insiders?
Are insiders buying or selling shares of OPKO Health?
In the last twelve months, OPKO Health insiders bought shares 24 times. They purchased a total of 10,561,267 shares worth more than $10,842,230.05. In the last twelve months, insiders at the biotechnology company sold shares 15 times. They sold a total of 736,644 shares worth more than $23,874,134.15. The most recent insider tranaction occured on December, 13th when CEO Phillip Md Et Al Frost bought 125,000 shares worth more than $198,750.00. Insiders at OPKO Health own 47.3% of the company.
Learn More about insider trades at OPKO Health. Information on this page was last updated on 12/13/2024.